Literature DB >> 9682295

Gliomatosis cerebri: a brain tumour which is too difficult to treat?

D Choi1, U Schulz, K Seex.   

Abstract

Gliomatosis cerebri is a rare form of primary diffuse brain tumour first described by Nevin in 1938. It was originally considered to be a post-mortem diagnosis before Troost et al reported a clinically diagnosed case in 1987. However antemortem diagnosis remains difficult due to vague clinical symptoms and often non-specific findings on CT scanning. Gliomatosis cerebri has been classified by the World Health Organization as an infiltrative tumoural process, which involves at least two, and usually three, lobes of the brain. Magnetic resonance (MR) imaging shows a diffuse infiltrative process with possible mass effect but no necrosis. Histology is usually of a low grade astrocytic neoplasm which seemingly infiltrates out of proportion to the degree of anaplasia. We report two patients who presented over the past year, whose clinical and radiological features prompted a preoperative diagnosis of gliomatosis cerebri, confirmed by biopsy.

Entities:  

Mesh:

Year:  1998        PMID: 9682295     DOI: 10.1177/003693309804300308

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  3 in total

1.  Histological and genetic diagnosis of gliomatosis cerebri: case report.

Authors:  S M Yamada; Y Hayashi; H Takahashi; A Teramoto; K Matsumoto; S Yamada
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

2.  Impact of adjuvant chemotherapy for gliomatosis cerebri.

Authors:  Doo-Sik Kong; Sung Tae Kim; Jung-Il Lee; Yeon-Lim Suh; Do Hoon Lim; Won Seog Kim; Ki-Hoon Kwon; Kwan Park; Jong Hyun Kim; Do-Hyun Nam
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430

3.  Presentation patterns and outcome of gliomatosis cerebri.

Authors:  Gustavo G Rajz; Dvora Nass; Elisa Talianski; Raphael Pfeffer; Roberto Spiegelmann; Zvi R Cohen
Journal:  Oncol Lett       Date:  2011-10-18       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.